USFDA grants QIDP Designation to Venus Remedies’ investigational product VRP-034

17 Apr 2025 Evaluate

United States Food and Drug Administration (USFDA) has granted Qualified Infectious Disease Product (QIDP) Designation to Venus Remedies’ investigational product VRP-034, for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adults. 

Developed by Venus Medicine Research Centre (VMRC), the R&D division of Venus Remedies, VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to address the nephrotoxic effects associated with conventional polymyxin B therapy. The QIDP designation, granted under the Generating Antibiotic Incentives Now (GAIN) Act. provides VRP-034 with significant regulatory benefits, including priority review, eligibility for fast-track designation, and an additional five years of market exclusivity upon approval in the United States. This recognition by USFDA strengthens Venus Remedies’ commitment to innovation in the fight against AMR and underlines the company’s dedication to addressing unmet needs in infectious disease therapy. 

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.


Venus Remedies Share Price

745.20 -7.70 (-1.02%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×